Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Nutex Health, Inc.NASDAQ: NUTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation turns negative
Q1 FY2026 stock-based compensation was -$3.92M, compared with $36.09M a year earlier. Trailing-twelve-month stock-based compensation was $85.45M. Over 3 fiscal years it compounded at +751.4% a year.
Context
- Stock-based compensation amounted to 13.4% of revenue in FY2025, up 9.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near -$3.92M or moves back toward the trailing-twelve-month quarterly average of $21.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 117M USD
- Year-over-year change
- +603.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 117M | +603.5% |
| FY2024 | 2024-12-31 | 16.63M | +486.5% |
| FY2023 | 2023-12-31 | 2.84M | +1395.9% |
| FY2022 | 2022-12-31 | 189.58K | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's LTM Mar 2026 stock-based compensation of $85.45M is the 2nd largest of the 11 companies compared; the peer median is $33.97M.
- Its year-over-year change of +62.2% is the 2nd highest of 10, against a peer median of -7.1%.
- Stock-based compensation amounts to 9.7% of revenue for NUTX, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $88M | +22.2% | +22.9% | 0.4% | |
| LTM Mar 2026 | $85.45M | +62.2% | +751.4% | 9.7% | |
| LTM Jun 2026 | $58M | +17.9% | — | 0.9% | |
| LTM Jun 2026 | $48.37M | -51.1% | +3.9% | 0.3% | |
| LTM Mar 2026 | $40.69M | +11.2% | +33.8% | 1.2% | |
| LTM Mar 2026 | $38.65M | -23.4% | +20.1% | 0.7% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $29.29M | +216.2% | +300.6% | 0.5% |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $5.93M | -7.1% | — | 0.3% |
| LTM Sep 2026 | $3.8M | -83.6% | -7.0% | 0.1% | |
| LTM Mar 2026 | $3.36M | -56.6% | +26.8% | 0.4% | |
| LTM Mar 2026 | $3M | — | — | 0.0% | |
| Peer median (excluding NUTX) | $33.97M | -7.1% | +22.9% | 0.4% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 168.53M | (432.74M) | (43.42M) | 95.27M | 180.36M |
| Depreciation & Amortization | 7.66M | 13.13M | 17.59M | 18.97M | 20.53M |
| Deferred Income Tax | 0 | 5M | (5.71M) | (13.13M) | 17.08M |
| Stock-Based Compensation | 0 | 189.58K | 2.84M | 16.63M | 117M |
| Change in Working Capital | 2.75M | 64.32M | (1.66M) | (104.4M) | (87.74M) |
| Accounts Receivables | (6.62M) | 58.08M | (4.58M) | (173.41M) | (89.32M) |
| Inventory | (1.09M) | (719.11K) | 142.7K | 540.77K | (16K) |
| Accounts Payables | 6.27M | 9.69M | (2.25M) | (10.72M) | 37.85M |
| Other Working Capital | 4.2M | (2.73M) | 5.03M | 79.19M | (36.26M) |
| Other Non-Cash Items | (5.51M) | 400.71M | 31.62M | 9.81M | 902K |
| Operating Cash Flow | 173.43M | 50.61M | 1.26M | 23.15M | 248.13M |
| Capital Expenditures | (36.93M) | (14.63M) | (9.5M) | (2.3M) | (2.53M) |
| Acquisitions (Net) | (48.85K) | 10.3M | (1.74M) | (361.33K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.6M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (4.31M) |
| Investing Cash Flow | (36.98M) | (4.34M) | (11.24M) | (2.67M) | (5.24M) |
| Debt Repayment | (3.22M) | (5.59M) | 2.65M | (7.4M) | (19.44M) |
| Common Stock Issued | 0 | 4.76M | 0 | 9.2M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (5M) |
| Dividends Paid | (144.34M) | (51.23M) | (5.21M) | (6.44M) | (74.28M) |
| Other Financing Activities | 21.71M | 3.93M | 298.03K | 5.73M | 767K |
| Financing Cash Flow | (125.85M) | (48.13M) | (2.27M) | 1.09M | (97.95M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 10.6M | (1.86M) | (12.25M) | 21.58M | 144.93M |
| Free Cash Flow | 136.51M | 35.97M | (8.24M) | 20.85M | 245.6M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.